Anti-PCSK9 [508.20.33b (Fab33)]
Catalogue Number: AB02938-2.0-ABA
| Manufacturer: | Vector Laboratories, Inc (ABA) |
| Type: | Recombinant Monoclonal |
| Alias: | NARC1; NARC-1; PC9; Proprotein convertase subtilisin/kexin type; Neural apoptosis-regulated convertase 1; Proprotein convertase 9; Subtilisin/kexin-like protease PC9 |
| Shipping Condition: | Blue Ice |
| Unit(s): | 200 ug |
| Host name: | Mouse |
| Clone: | 508.20.33b (Fab33) |
| Isotype: | IgG2a |
| Immunogen: | The original antibody was isolated from a phage display library by panning against biotinylated human PCSK9. |
| Application: | ELISA, FA, Blk, Ant |
Additional Text
Uniprot ID
Q8NBP7
Gene Name
PCSK9
Gene ID
255738
Purification
Purified
Antibody Clonality
Recombinant Monoclonal
Storage Note
Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at -20⁰C.
Application Notes
The binding affinity of this antibody towards PCSK9 protein from human, murine, rhesus, and cynomolgus monkey was done using surface plasmon resonance. This antibody was found to inhibit binding of PCSK9 to LDLR in a competition binding ELISA. This antibody plays a role in effective prevention of LDLR downregulation in HepG2 cells in vitro. When administered in vivo, this antibody prevented LDLR downregulation in mouse liver. This antibody showed a reduction in total serum cholesterol levels in mice when a single dose of 10 mg/kg was administered. It was also found that a combination of this antibody and statin results in a greater reduction in total cholesterol level compared to anti-PCSK9 antibody alone or statin alone treatments (US9266961). A randomized, double-blind, placebo-controlled, single and multiple dose study was conducted to evaluate, primarily, the safety and tolerability of single and multiple (four weekly) doses of reformatted IgG1 version of this antibody when administered by subcutaneous (SC) injection to healthy volunteers with elevated serum low-density lipoprotein cholesterol (LDL-c) concentration. It was found that there were no serious or severe adverse events, no discontinuations for adverse events, and no dose-limiting toxicities (US9266961).
Short Description
This chimeric mouse antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques.
AB02938-2.0 Datasheet
SUPPORT
outstanding technical support
PRODUCT
we offer a full product guarantee
DELIVERY
we offer free delivery to UK universities and non profit organisations